Detalles de la búsqueda
1.
Dolutegravir as First- or Second-Line Treatment for HIV-1 Infection in Children.
N Engl J Med
; 385(27): 2531-2543, 2021 12 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34965338
2.
Reduced and highly diverse peripheral HIV-1 reservoir in virally suppressed patients infected with non-B HIV-1 strains in Uganda.
Retrovirology
; 19(1): 1, 2022 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35033105
3.
Plasma Inflammatory Biomarkers Predict CD4+ T-cell Recovery and Viral Rebound in HIV-1 Infected Africans on Suppressive Antiretroviral Therapy.
J Infect Dis
; 224(4): 673-678, 2021 08 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-33373447
4.
High-level resistance to bictegravir and cabotegravir in subtype A- and D-infected HIV-1 patients failing raltegravir with multiple resistance mutations.
J Antimicrob Chemother
; 76(11): 2965-2974, 2021 10 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34453542
5.
ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
BMC Infect Dis
; 21(1): 5, 2021 Jan 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-33446115
6.
Accumulation of integrase strand transfer inhibitor resistance mutations confers high-level resistance to dolutegravir in non-B subtype HIV-1 strains from patients failing raltegravir in Uganda.
J Antimicrob Chemother
; 75(12): 3525-3533, 2020 12 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32853364
7.
Plasma Biomarkers of Human Immunodeficiency Virus-Related Systemic Inflammation and Immune Activation in Sub-Saharan Africa Before and During Suppressive Antiretroviral Therapy.
J Infect Dis
; 220(6): 1029-1033, 2019 08 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31086991
8.
Association Between Single-Nucleotide Polymorphisms in HLA Alleles and Human Immunodeficiency Virus Type 1 Viral Load in Demographically Diverse, Antiretroviral Therapy-Naive Participants From the Strategic Timing of AntiRetroviral Treatment Trial.
J Infect Dis
; 220(8): 1325-1334, 2019 09 13.
Artículo
en Inglés
| MEDLINE | ID: mdl-31219150
9.
Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.
J Infect Dis
; 214(6): 873-83, 2016 09 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27402780
10.
Low-Frequency Drug Resistance in HIV-Infected Ugandans on Antiretroviral Treatment Is Associated with Regimen Failure.
Antimicrob Agents Chemother
; 60(6): 3380-97, 2016 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-27001818
11.
Accumulation of HIV-1 drug resistance after continued virological failure on first-line ART in adults and children in sub-Saharan Africa.
J Antimicrob Chemother
; 71(10): 2918-27, 2016 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-27342546
12.
Pretreatment HIV drug resistance increases regimen switches in sub-Saharan Africa.
Clin Infect Dis
; 61(11): 1749-58, 2015 Dec 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26240203
13.
Specific plasma microRNAs are associated with CD4 + T-cell recovery during suppressive antiretroviral therapy for HIV-1.
AIDS
; 38(6): 791-801, 2024 May 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-38300257
14.
Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multicountry longitudinal cohort analysis.
AIDS
; 36(10): 1437-1447, 2022 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35608116
15.
Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority ODYSSEY trial.
Lancet HIV
; 9(9): e627-e637, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35868341
16.
Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial.
Lancet HIV
; 9(9): e638-e648, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-36055295
17.
Monocyte activation in persons living with HIV and tuberculosis coinfection.
AIDS
; 35(3): 447-452, 2021 03 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-33252496
18.
The relative contributions of HIV drug resistance, nonadherence and low-level viremia to viremic episodes on antiretroviral therapy in sub-Saharan Africa.
AIDS
; 34(10): 1559-1566, 2020 08 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32675566
19.
Persistence of traditional and emergence of new structural drivers and factors for the HIV epidemic in rural Uganda; A qualitative study.
PLoS One
; 14(11): e0211084, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31693660
20.
Changes over time in creatinine clearance and comparison of emergent adverse events for HIV-positive adults receiving standard doses (300 mg/day) of lamivudine-containing antiretroviral therapy with baseline creatinine clearance of 30-49 vs ≥50 mL/min.
PLoS One
; 14(11): e0225199, 2019.
Artículo
en Inglés
| MEDLINE | ID: mdl-31725787